By depleting CTLA-4-expressing Tregs in the TME via antibody-dependent cellular cytotoxicity, ipilimumab enhances anti-tumor immune responses and was the first immune checkpoint inhibitor to gain FDA approval in 2011 [128,129,130]. Here, CTLA4 is linked to neoplasm.